Feature | August 30, 2011

Low-Risk Patients Fare the Same With Transcatheter Aortic Valve vs. Surgery

August 30, 2011 – Results from a study presented at the European Society of Cardiology (ESC) Congress 2011 show that transcatheter aortic-valve implantation (TAVI) in low-risk patients met with 100 percent procedural success (versus 95.3 percent in the high Euroscore group (p=0.1). While researchers expected a lower mortality among patients with low Euroscore, the observed difference was much greater than anticipated.  In fact, the mortality rates with the Edwards Sapien valve have approached the results with conventional surgery.

The results represent a first step towards a broader assessment of percutaneous techniques in populations at lower surgical risk but without forgetting that surgery is currently the gold standard, said Matthieu Godin, M.D., from the University Hospital of Rouen, France.

“The most interesting point to observe is the absence of death at one month in the low Euroscore group, versus a mortality rate of 11.1 percent in the high Euroscore group (>20 percent), (p < 0.04) and this result is confirmed at one-year with 5 versus 24.8 percent, (p<0.01). While we were expecting a lower mortality among patients with low Euroscore, the observed difference was much greater than anticipated. In fact, the mortality rates have approached the results with conventional surgery,” Godin said.

Aortic stenosis is the most frequently acquired valve disease in adults. Two percent are symptomatic and thus should require aortic valve replacement because, in this disease, a long latency is followed by rapid progression after the appearance of symptoms, with more than half of patients dying within two years. It can be estimated that with the aging population, within 15 years, the number of aortic stenosis patients will double.

After more than 15 years of research, the first-in-man percutaneous valve implantation was performed in the center at the University Hospital of Rouen by Alain Cribier in April 2002. Since then, about 40,000 patients have been implanted worldwide with the use of two different models of valve: the balloon expandable valve and the self-expanding device. The CE mark was obtained for both in 2007. TAVI can today be proposed as an alternative treatment and has recently demonstrated its great efficiency with the results of the pivotal PARTNER-US trial. 
 
Based on the recommendations of both the ESC and the European Society of Cardiac Surgery, most of the registries have so far only included patients with high logistic Euroscore > 20 percent (a system developed to predict the operative mortality of coronary surgery).

In view of the overall good results in this high-risk population, a significant trend to include lower risk patients in Europe has been observed. The last registries have seen their Euroscore decreasing to 15 percent and some prospective trials are planned to include patients whatever their score.

“We sought to evaluate the results obtained in our subgroup of patients with a low Euroscore. It does not mean that the patients were at very low risk for TAVI, since they had been considered as having surgical contraindication, which did not affect the Euroscore (radiotherapy, corticosteroids, thoracic deformation or porcelain aorta). However, the patients were often less sick and younger and it seemed interesting to assess the results in this population,” said Godin.

This study is a retrospective study from all 177 patients implanted with the Edwards prosthesis at the Rouen center between May 2006 and January 2011. Patients were divided into two groups according to their predictive Logistic Euroscore: High Euroscore (>20 percent) vs Low Euroscore (<20 percent).

For more information: www.escardio.org

Related Content

Sponsored Content | Videos | EP Lab| May 26, 2017
DAIC Editor Dave Fornell takes a tour of some of the most innovative new electrophysiology (EP) technology at the 201
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery| May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve
News | Heart Valve Technology| May 24, 2017
May 24, 2017 — Late-breaking data presented at EuroPCR 2017 demonstrating excellent clinical outcomes for...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery| May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Nearly One-Quarter of Patients Say Mechanical Heart Valve Disturbs Sleep
News | Heart Valve Technology| May 19, 2017
Nearly one-quarter of patients with a mechanical heart valve say it disturbs their sleep, according to research...
Analysis Looks at Role Type of Valve Plays in Patient Outcomes Post-TAVR
News | Heart Valve Technology| May 15, 2017
For patients who undergo transcatheter aortic valve replacement (TAVR), their risk factors, not the type of valve used...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery| May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
Baylor Jack and Jane Hamilton Heart and Vascular Hospital Implants CoreValve Evolut Pro Valve
News | Heart Valve Technology| May 03, 2017
The Baylor Jack and Jane Hamilton Heart and Vascular Hospital (BHVH) transcatheter aortic valve replacement (TAVR) team...
Overlay Init